Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin H Lachmann

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|March 3, 2006
Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disordersRobin H Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Miglustat. Oxford GlycoSciences/ActelionRobin H Lachmann
Current Opinion in Pediatrics|September 28, 2011
Enzyme replacement therapy for lysosomal storage diseasesRobin H Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|November 13, 2004
alpha-glucosidase (CHO) (Genzyme)Robin H Lachmann
Journal of Inherited Metabolic Disease|May 30, 2019
Treating lysosomal storage disorders: What have we learnt?Robin H Lachmann
Expert Review of Endocrinology & Metabolism|February 13, 2019
Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brainRobin H Lachmann
Practical Neurology|March 25, 2016
Homocysteine and methylmalonate: when should I measure them and what do they mean?Robin H Lachmann, Anthony Briddon
Practical Neurology|July 3, 2024
When to suspect inherited metabolic diseasesSamuel Shribman, Robin H Lachmann
Clinical Medicine (London, England)|January 20, 2009
Acute presentations of inherited metabolic disease in adulthoodPhilip J Lee, Robin H Lachmann
Biochimica Et Biophysica Acta|October 1, 2008
Treating lysosomal storage disorders: current practice and future prospectsFrances M Platt, Robin H Lachmann
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Drugs of Today (Barcelona, Spain : 1998)|March 3, 2006
Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disordersRobin H Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Miglustat. Oxford GlycoSciences/ActelionRobin H Lachmann
Current Opinion in Pediatrics|September 28, 2011
Enzyme replacement therapy for lysosomal storage diseasesRobin H Lachmann
Current Opinion in Investigational Drugs (London, England : 2000)|November 13, 2004
alpha-glucosidase (CHO) (Genzyme)Robin H Lachmann
Journal of Inherited Metabolic Disease|May 30, 2019
Treating lysosomal storage disorders: What have we learnt?Robin H Lachmann
Expert Review of Endocrinology & Metabolism|February 13, 2019
Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brainRobin H Lachmann
Practical Neurology|March 25, 2016
Homocysteine and methylmalonate: when should I measure them and what do they mean?Robin H Lachmann, Anthony Briddon
Practical Neurology|July 3, 2024
When to suspect inherited metabolic diseasesSamuel Shribman, Robin H Lachmann
Clinical Medicine (London, England)|January 20, 2009
Acute presentations of inherited metabolic disease in adulthoodPhilip J Lee, Robin H Lachmann
Biochimica Et Biophysica Acta|October 1, 2008
Treating lysosomal storage disorders: current practice and future prospectsFrances M Platt, Robin H Lachmann
Pageof 6